417 related articles for article (PubMed ID: 11064877)
1. The efficacy and cost effectiveness of new antiemetic guidelines.
Engstrom C; Hernandez I; Haywood J; Lilenbaum R
Oncol Nurs Forum; 1999 Oct; 26(9):1453-8. PubMed ID: 11064877
[TBL] [Abstract][Full Text] [Related]
2. Nurses' perceptions of antiemetic effectiveness.
Rhodes VA; McDaniel RW; Simms SG; Johnson M
Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
[TBL] [Abstract][Full Text] [Related]
3. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
4. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
5. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
Goodman M
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378
[TBL] [Abstract][Full Text] [Related]
7. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
Kwong WJ; Parasuraman TV
Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
10. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
[TBL] [Abstract][Full Text] [Related]
12. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
13. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
Herrstedt J
Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
[TBL] [Abstract][Full Text] [Related]
14. Clinical practice guidelines on antiemetics in oncology.
Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
[TBL] [Abstract][Full Text] [Related]
15. Relieving nausea and vomiting in patients with cancer: a treatment algorithm.
Johnson MH; Moroney CE; Gay CF
Oncol Nurs Forum; 1997; 24(1):51-7. PubMed ID: 9007907
[TBL] [Abstract][Full Text] [Related]
16. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.
O'Brien BJ; Rusthoven J; Rocchi A; Latreille J; Fine S; Vandenberg T; Laberge F
CMAJ; 1993 Aug; 149(3):296-302. PubMed ID: 8339175
[TBL] [Abstract][Full Text] [Related]
17. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment--how are we doing?
Grunberg SM
J Support Oncol; 2004; 2(1 Suppl 1):1-10, inside back cover; quiz 11. PubMed ID: 16117016
[TBL] [Abstract][Full Text] [Related]
20. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]